Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신수진 | - |
dc.date.accessioned | 2017-12-15T02:18:28Z | - |
dc.date.available | 2017-12-15T02:18:28Z | - |
dc.date.issued | 2016-02 | - |
dc.identifier.citation | ANNALS OF SURGICAL ONCOLOGY, v. 23, NO 2, Page. 694-702 | en_US |
dc.identifier.issn | 1068-9265 | - |
dc.identifier.issn | 1534-4681 | - |
dc.identifier.uri | https://link.springer.com/article/10.1245%2Fs10434-015-4903-7 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/34153 | - |
dc.description.abstract | Immune checkpoint blockade therapy targeting programmed death (PD)-1 or PD-ligand1 (L1) has shown promising results in renal cell carcinoma (RCC); however, the prognostic implications and clinicopathological features of PD-L1 and PD-L2 expression in RCC remain unclear. PD-L1 and PD-L2 expression was immunohistochemically evaluated in 425 resected RCCs of variable histologic subtypes and analyzed according to the clinicopathological status and oncogenic proteins status. PD-L1 expression was observed in 9.4 % with no difference between histologic subtypes, but PD-L2 was observed in 49.6 % with highest frequency in papillary RCC (PRCC) (P < 0.001). In clear cell RCC (CCRCC), PD-L1 expression was associated with adverse features, including higher nuclear grade, necrosis, sarcomatoid transformation, c-MET expression (all, P < 0.001) and VEGF expression (P = 0.002), whereas PD-L2 expression was related with c-MET and VEGF expression (P = 0.008 and P < 0.001). In PRCC, positive correlations between PD-L1 and EGFR expression (P = 0.007) or between PD-L2 and VEGF expression (P < 0.001) were observed. In CCRCC, PD-L1 and PD-L2 positivity were significantly associated with shorter progression-free survival (P < 0.001; P = 0.033) and cancer-specific survival (P < 0.001; P = 0.010), but not in PRCC. PD-L1 and PD-L2 expression predict poor prognosis in CCRCC. Thus, PD-1/PD-L pathway-targeted immunotherapy may be useful for treatment of patients with CCRCC. | en_US |
dc.language.iso | en | en_US |
dc.publisher | SPRINGER | en_US |
dc.subject | PHASE-III TRIAL | en_US |
dc.subject | ANTITUMOR IMMUNITY | en_US |
dc.subject | B7-H1 | en_US |
dc.subject | CANCER | en_US |
dc.subject | ACTIVATION | en_US |
dc.subject | ANTIBODY | en_US |
dc.subject | INTERLEUKIN-2 | en_US |
dc.subject | PAZOPANIB | en_US |
dc.subject | MECHANISM | en_US |
dc.subject | BLOCKADE | en_US |
dc.title | Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status | en_US |
dc.type | Article | en_US |
dc.relation.no | 2 | - |
dc.relation.volume | 23 | - |
dc.identifier.doi | 10.1245/s10434-015-4903-7 | - |
dc.relation.page | 694-702 | - |
dc.relation.journal | ANNALS OF SURGICAL ONCOLOGY | - |
dc.contributor.googleauthor | Shin, Su-Jin | - |
dc.contributor.googleauthor | Jeon, Yoon Kyung | - |
dc.contributor.googleauthor | Kim, Pil-Jong | - |
dc.contributor.googleauthor | Cho, Yong Mee | - |
dc.contributor.googleauthor | Koh, Jaemoon | - |
dc.contributor.googleauthor | Chung, Doo Hyun | - |
dc.contributor.googleauthor | Go, Heounjeong | - |
dc.relation.code | 2016003224 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | charm | - |
dc.identifier.orcid | http://orcid.org/0000-0001-9114-8438 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.